AGC Biologics Secures CDMO Contract with Teikoku Seiyaku for Recombinant rhMMP-7 Drug Substance, GMP Production at Chiba Plant

AGC Biologics Japan

Overview

AGC Biologics has signed a CDMO contract with Teikoku Seiyaku Co. for the microbial drug substance manufacturing of recombinant human matrix metalloproteinase-7 (rhMMP-7) ‘KTP-001′. Initial cell bank creation will take place in Heidelberg, Germany, followed by process development and GMP manufacturing for clinical trials at AGC Biologics’ Chiba facility in Japan. This collaboration leverages AGC Biologics’ global microbial manufacturing network, ensuring supply chain security and flexibility to support Teikoku Seiyaku’s innovative therapeutic development.

In Depth

Key Findings

AGC Biologics has entered into a contract to provide its Contract Development and Manufacturing Organization (CDMO) services for Teikoku Seiyaku Co., Ltd.’s recombinant human matrix metalloproteinase-7 (rhMMP-7) drug substance, KTP-001. This strategic partnership will see the GMP manufacturing for clinical trials of KTP-001 conducted at AGC Biologics’ Chiba facility in Japan, marking a significant advancement in Teikoku Seiyaku’s innovative drug development pipeline.

Technical / Clinical Details

KTP-001 is a recombinant protein with anticipated applications in various disease treatments, requiring sophisticated microbial fermentation technology for its production. The initial phase of this project involves cell bank creation at AGC Biologics’ facility in Heidelberg, Germany. Subsequently, process development optimization and GMP (Good Manufacturing Practice) manufacturing of the investigational drug for clinical trials will transition to the Chiba plant in Japan. AGC Biologics is one of the few CDMOs globally with microbial manufacturing capabilities across three continents (Europe, North America, and Asia), offering Teikoku Seiyaku the benefits of a geographically diversified and robust supply chain.

Background & Context

In the development of biopharmaceuticals, particularly recombinant proteins, establishing high-quality standards and efficient manufacturing processes is paramount. Partnering with a CDMO allows developing companies to focus their resources on R&D while leveraging specialized manufacturing expertise and large-scale facilities. Furthermore, supply chain diversification is increasingly crucial in today’s global drug development landscape to mitigate geopolitical risks and unforeseen supply disruptions. AGC Biologics’ Japanese site also offers favorable access to the burgeoning Asian market.

Strategic Significance & Outlook

This agreement is expected to accelerate the clinical development of KTP-001 and further solidify AGC Biologics’ standing as a leading microbial biopharmaceutical CDMO. Teikoku Seiyaku aims for rapid progression through clinical trials and eventual product commercialization, supported by a stable supply of high-quality drug substance. The collaboration exemplifies the critical importance of technological expertise and strategic manufacturing capacity in the global pharmaceutical development ecosystem, ultimately contributing to the provision of new therapies to patients.